GSK PLC-SPON ADR (GSK) Stock Overview
USA - NYSE:GSK - US37733W2044 - ADR
GSK Key Statistics, Chart & Performance
The current stock price of GSK is 45.93 USD. In the past month the price increased by 0.92%. In the past year, price increased by 24.54%.
GSK Latest News, Press Relases and Analysis
GSK Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 50.37 | 769.97B | ||
| JNJ | JOHNSON & JOHNSON | 17.98 | 449.40B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 18.52 | 254.96B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.47 | 235.79B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 13.21 | 228.26B | ||
| MRK | MERCK & CO. INC. | 11.24 | 216.26B | ||
| PFE | PFIZER INC | 7.17 | 138.10B | ||
| SNY | SANOFI-ADR | 11.47 | 123.51B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 6.33 | 86.71B | ||
| ZTS | ZOETIS INC | 23.14 | 63.79B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 49.18 | 43.49B | ||
| HLN | HALEON PLC-ADR | 18.47 | 40.30B |
Related stock screener links
About GSK
Company Profile
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. The company is headquartered in Brentford, Middlesex and currently employs 68,629 full-time employees. The Company’s segments include Commercial Operations and Research and Development. Its portfolio and pipeline are focused on developing medicines and vaccines in four core therapeutic areas, which are the areas of human health it focuses on to prevent and treat disease: respiratory, immunology and inflammation; oncology; HIV; and infectious diseases. Its specialty medicines prevent and treat diseases, from human immunodeficiency virus (HIV) to respiratory diseases, immune-mediated conditions like lupus, and cancer. Its vaccine portfolio includes over 20 vaccines to protect people from a range of diseases and infections throughout their lives. General medicines include inhaled medicines for asthma and COPD, antibiotics and medicines for skin diseases. Its portfolio also includes Efimosfermin, a fibroblast growth factor 21 (FGF21) analog therapeutic in clinical development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).
Company Info
GSK PLC-SPON ADR
980 Great West Road
Brentford MIDDLESEX TW8 9GS GB
CEO: Emma Walmsley
Employees: 68629
Phone: 442080475000
GSK PLC-SPON ADR / GSK FAQ
Can you describe the business of GSK PLC-SPON ADR?
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. The company is headquartered in Brentford, Middlesex and currently employs 68,629 full-time employees. The Company’s segments include Commercial Operations and Research and Development. Its portfolio and pipeline are focused on developing medicines and vaccines in four core therapeutic areas, which are the areas of human health it focuses on to prevent and treat disease: respiratory, immunology and inflammation; oncology; HIV; and infectious diseases. Its specialty medicines prevent and treat diseases, from human immunodeficiency virus (HIV) to respiratory diseases, immune-mediated conditions like lupus, and cancer. Its vaccine portfolio includes over 20 vaccines to protect people from a range of diseases and infections throughout their lives. General medicines include inhaled medicines for asthma and COPD, antibiotics and medicines for skin diseases. Its portfolio also includes Efimosfermin, a fibroblast growth factor 21 (FGF21) analog therapeutic in clinical development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).
What is the current price of GSK stock?
The current stock price of GSK is 45.93 USD. The price increased by 5.1% in the last trading session.
Does GSK PLC-SPON ADR pay dividends?
GSK PLC-SPON ADR (GSK) has a dividend yield of 3.89%. The yearly dividend amount is currently 1.62.
What is the ChartMill rating of GSK PLC-SPON ADR stock?
GSK has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
What is the GICS sector and industry of GSK stock?
GSK PLC-SPON ADR (GSK) operates in the Health Care sector and the Pharmaceuticals industry.
What is the next earnings date for GSK stock?
GSK PLC-SPON ADR (GSK) will report earnings on 2025-10-29, before the market open.
What is the ownership structure of GSK PLC-SPON ADR (GSK)?
You can find the ownership structure of GSK PLC-SPON ADR (GSK) on the Ownership tab.
GSK Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to GSK. When comparing the yearly performance of all stocks, GSK is one of the better performing stocks in the market, outperforming 81.58% of all stocks.
GSK Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to GSK. While GSK has a great profitability rating, there are some minor concerns on its financial health.
GSK Financial Highlights
Over the last trailing twelve months GSK reported a non-GAAP Earnings per Share(EPS) of 4.46. The EPS decreased by -0.9% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 10.82% | ||
| ROA | 5.78% | ||
| ROE | 23.14% | ||
| Debt/Equity | 1.03 |
GSK Forecast & Estimates
31 analysts have analysed GSK and the average price target is 44.36 USD. This implies a price decrease of -3.42% is expected in the next year compared to the current price of 45.93.
For the next year, analysts expect an EPS growth of 4.82% and a revenue growth 3.11% for GSK